Application of medicine in prevention and treatment of HER2 expression positive solid tumor

By providing compounds of formula I and their compositions, the problem of insufficient inhibitory activity of existing drug cells is solved for HER2-expressing solid tumors, effectively inhibiting HER2-expressing tumors is achieved, and new therapeutic options are provided.

CN119015285APending Publication Date: 2024-11-26HANGZHOU BANGSHUN PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411021037.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-02-17
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

When the existing HER2 target drugs are treated with solid tumors with positive HER2 expression, the cell inhibitory activity is insufficient and cannot meet clinical needs. They need a HER2 target drug with stronger efficacy.

Method used

Provided is a compound of formula I and a pharmaceutically acceptable salt or composition thereof, which is used to prevent or treat HER2 expression-positive solid tumors, including breast cancer and gastric cancer, by inhibiting the effect of HER2 kinase and inhibiting the proliferation of HER2-positive tumor cells. etc., and can be used in combination with other drugs.

Benefits of technology

Compounds of formula I show strong inhibitory effects of HER2 kinase and significant inhibitory effects on HER2-expressive tumor cells, which are better than existing HER2-expressive tumor treatment drugs, providing new therapeutic options.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015285A_ABST
    Figure CN119015285A_ABST
Patent Text Reader

Abstract

The invention provides application of a compound shown as a formula I or medicinal salt thereof in preparation of a medicine for preventing or treating HER2 expression positive solid tumors. In test of HER2 expression positive kinase and cell strain inhibition of compound shown in formula I, # imgabs0 # shows extremely remarkable tumor growth inhibition treatment effect
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a new use of a drug, and in particular to use of a compound of formula I, a pharmaceutically acceptable salt or a composition thereof in the preparation of a drug for preventing and treating HER2-positive solid tumors. Background Art

[0002] The human epidermal growth factor receptor (HER) family includes HER1 (erbB1, EGFR), HER2 (erbB2, NEU), HER3 (erbB3) and HER4 (erbB4). The HER family plays an important regulatory role in cell physiological processes. Most somatic mutations of the HER2 gene have been shown to activate and drive the occurrence and development of tumors. HER2 has no known ligands. It forms heterodimers with other family members. The ligands of other members activate EGFR, HER-3 or HER-4 kinases through heterodimer interactions, and activate downstream signal transduction pathways through receptor phosphorylation, mainly by acting on downstream Ras-Raf-Mek-MAPK, PI3K-Akt-mTOR, etc., thereby affecting cell proliferation, cell cycle regulation, apoptosis, angiogenesis and other processes.

[0003] HER2 is one of the important targets for solid tumor treatment. Many HER2-targeted drugs (tyrosine kinase inhibitors, antibody drugs, ADC) have been approved for the treatment of breast cancer and gastric cancer. Several approved HER2 tyrosine kinase inhibitors (TKIs), antibodies and ADC drugs have shown good efficacy in a variety of HER2-positive malignant solid tumors, including Lapatinib, Neratinib and Trastuzumab. However, there are still unmet needs in clinical practice, such as insufficient cell inhibition activity, and a more potent HER2-targeted drug is needed.

[0004] The compound of formula I was first disclosed in Chinese patent CN201510405448.6 (invention name: Anilinopyrimidine derivatives and their use in the preparation of anti-malignant tumor drugs). Summary of the invention

[0005] The object of the present invention is to provide the use of a compound of formula I, a pharmaceutically acceptable salt thereof or a composition thereof in the preparation of a drug for preventing or treating HER2-positive solid tumors, thereby providing a new therapeutic approach for the prevention or treatment of HER2-positive solid tumors and increasing the drug treatment options for HER2-positive solid tumors.

[0006] The purpose of the present invention can be achieved through the following technical solutions:

[0007] The present invention provides a use of a compound of formula I, a pharmaceutically acceptable salt thereof or a composition thereof in the preparation of a drug for treating or preventing HER2-positive solid tumors:

[0008]

[0009] Among them, HER2-expressing solid tumors refer to a group of diseases that carry the HER2 gene, including various malignant tumors.

[0010] In some embodiments, the solid tumors include but are not limited to breast cancer, gastric cancer, gastrointestinal cancer, esophageal gastric junction cancer, lung cancer, ovarian cancer, bladder cancer, tonsil tumors, oral cancer, laryngeal tumors, brain cancer, cervical cancer, colon cancer, rectal cancer, colorectal cancer, peritoneal cancer, biliary tract cancer, esophageal adenocarcinoma and esophageal cancer.

[0011] In some embodiments, the solid tumor comprises a brain metastasis of a solid tumor.

[0012] The present invention proves that the compound of formula I has a good inhibitory effect on HER2 positive solid tumors by testing its proliferation inhibitory effect on HER2 kinase and HER2 positive tumor cell lines (HCC1569, HCC202, MKN7, NCI-H2170, SK-OV-3, TE-4, UACC-893, UACC-812 and ZR-75-30, etc.).

[0013] The present invention also provides a use of a composition in preparing a drug for preventing or treating HER2-positive solid tumors, wherein the composition comprises an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0014] The composition provided by the present invention includes, in addition to the compound of formula I and its salt, one or more pharmaceutically acceptable carriers, diluents or excipients. The carriers, diluents or excipients must be compatible with the other components in the preparation and harmless to the recipient.

[0015] The composition provided by the present invention can be used for the prevention and treatment of solid tumors including but not limited to breast cancer, gastric cancer, gastrointestinal cancer, esophageal gastric junction cancer, lung cancer, ovarian cancer, bladder cancer, tonsil tumors, oral cancer, laryngeal tumors, brain cancer, cervical cancer, colon cancer, rectal cancer, colorectal cancer, peritoneal cancer, biliary tract cancer, esophageal adenocarcinoma and esophageal cancer.

[0016] The composition provided by the present invention can be used to prevent or treat brain metastases of solid tumors.

[0017] The composition of the present invention can also be used in combination with other one or more drugs (chemotherapeutic drugs and / or targeted drugs). When adopting combined therapy, therapeutic agents can be administered together or separately, and the same or different modes of administration can be adopted. When therapeutic agents are administered separately, they can be administered simultaneously or in any order. The relative time of formula I compound and / or other one or more pharmaceutically active agents and administration can be selected in order to achieve the required combined therapeutic effect.

[0018] The composition provided by the present invention can be in the form of capsules, tablets, powders, injections or external preparations.

[0019] The compound of formula I provided by the present invention has the following beneficial effects:

[0020] Kinase assays showed that the compound of formula I has a strong HER2 kinase inhibitory effect;

[0021] In vitro tumor cell proliferation inhibition experiments showed that the compound of formula I exhibited a strong inhibitory effect on HER2-positive tumor cell lines.

[0022] In summary, the compounds of formula I, their pharmaceutically acceptable salts or compositions thereof provided in the present application can achieve unexpected technical effects in treating or preventing HER2-positive solid tumors. DETAILED DESCRIPTION

[0023] In order to better understand the content of the present invention, the technical solution of the present invention is further described below in conjunction with specific embodiments, but the specific implementation methods do not mean any limitation to the present invention.

[0024] The compound of formula I was prepared according to the method of Example 6 of Chinese Patent CN201510405448.6.

[0025] Other drugs, reagents or materials were purchased commercially.

[0026] Example 1 HER2 kinase activity test

[0027] 1. Experimental Methods

[0028] The activity of the compound was tested using the mobility shift assay method as follows: the compound to be tested was dissolved in DMSO and prepared into a 50x stock solution of the final concentration required for the experiment. The starting concentration of the compound test was 10μM, 2-fold dilution, and 10 concentration gradients were configured. The mixed solution of kinase, ATP and Kinase substrate was prepared into a solution with a final concentration of 2.5 times using 1xKinase buffer. 10μL of 2.5x kinase solution was added to the detection wells of a 384-well plate to which 5μL of 10% DMSO compound solution had been added, and incubated at room temperature for 10 minutes. 10μL of the 2.5x ATP and Kinasesubstrate mixed solution was added to the detection wells of the 384-well plate and incubated at 28°C for the specified time. 25μL of stop detection solution was added to stop the kinase reaction, and data was collected using Caliper EZ Reader.

[0029] 2. Calculation of results

[0030] The dose-effect curve was fitted using analysis software to obtain the IC value of each compound for the inhibition of HER2 kinase activity. 50 (nM) values ​​are shown in the table below.

[0031] Table 1 Kinase inhibitory activity

[0032]

[0033] Example 2 Inhibitory effect of the compound of formula I on proliferation of HER2-positive tumor cell lines

[0034] HER2 expression positive tumor cell lines: HCC1569, HCC202, MKN7, NCI-H2170, SK-OV-3, TE-4, UACC-893, UACC-812 and ZR-75-30.

[0035] Table 2 Experimental cell lines

[0036] Cell lines source Part Number Genetic characteristics Cell species UACC-812 ATCC CRL-1897 HER2+ Breast cancer HCC1569 ATCC CRL-2330 HER2+ Breast cancer HCC202 ATCC CRL-2316 HER2+ Breast cancer UACC-893 ATCC CRL-1902 HER2+ Breast cancer ZR-75-30 ATCC CRL-1504 HER2+ Breast cancer MKN7 RIKEN RCB0999 HER2+ Gastric cancer NCI-H2170 ATCC CRL-5928 HER2+ Lung cancer SK-OV-3 ATCC HTB-77 HER2+ Ovarian cancer TE-4 RIKEN RCB2097 HER2+ Esophageal cancer

[0037] Other reagents and materials: fetal bovine serum, MEM medium, NEAA supplement, DMEM medium, RPMI 1640 medium, McCoy'5A medium, Hybricare medium, human epidermal growth factor, penicillin-streptomycin mixture, CellTiter-Glo, DMSO, glutamine, EDTA / trypsin and 96-well plate.

[0038] Test articles: Compound of formula I, Lapatinib, Neratinib.

[0039] Test method:

[0040] Take out the cultured cells from the incubator, remove the supernatant, digest with 5 ml of trypsin, terminate the trypsin digestion with 10 ml of culture medium, transfer the cell suspension to a 15 ml centrifuge tube, centrifuge at 1000 rpm for 5 minutes, resuspend the cells with 10 ml of culture medium, aspirate 1 ml of culture medium, and place in Vi-Cell XR to measure the number and viability of cells. Dilute the cells to a cell suspension of a specified density according to the measured cell density.

[0041] Use an electric spray gun to add the prepared cell suspension to a 96-well culture plate (#3903), 100 μL of cell suspension per well. Place in a 37°C / 5% carbon dioxide incubator for overnight culture. Take out the prepared drug stock solution, melt at room temperature, centrifuge at 1000 rpm for 1 minute and mix. Add the test compound to the well plate (10 μM starting, 3-fold dilution, double or single well, 10 concentrations), add the drug to the corresponding well using the HPD300 instrument, centrifuge at 1000 rpm for 1 minute, and place the culture plate in an incubator for 3 days.

[0042] After 3 days, the cell culture plate was taken out and placed under a microscope to observe the cell density. The cell plate was taken out and placed at room temperature for half an hour to balance, 100 μL CTG reagent was added, and after low-speed shaking on a shaker for 2 minutes, the plate was measured with the Enspire instrument and the data was processed.

[0043] The Log value of the concentration of the test drug was used as the horizontal axis, and the measured cell growth inhibition rate was used as the vertical axis. The IC50 of each compound on the cell line was calculated using EXCEL-XLFIT software.

[0044] The test results show that the compound of formula I has better inhibitory activity against various tumor cell lines than currently marketed HER2-expressing positive tumor therapeutic drugs.

[0045] Table 3 Cell inhibitory activity IC 50 Value (μM)

[0046] Cell lines UACC-812 Compounds of formula I 2.023 Laptinib >10 Neratinib >10

[0047] Table 4 Cell inhibitory activity IC 50 Value (μM)

[0048] Cell lines HCC1569 HCC202 UACC-893 ZR-75-30 MKN7 NCI-H2170 SK-OV-3 TE-4 Compounds of formula I 2.419 0.332 0.539 0.094 0.664 0.019 1.018 0.030 Laptinib 8.704 0.771 1.133 0.194 3.075 0.039 2.967 0.085

Claims

1. Use of a compound of formula I or a pharmaceutically acceptable salt thereof in the preparation of a drug for preventing or treating HER2-positive solid tumors 2. The use according to claim 1, wherein The solid tumors include breast cancer, gastric cancer, gastrointestinal cancer, esophageal gastric junction cancer, lung cancer, ovarian cancer, bladder cancer, tonsil tumors, oral cancer, laryngeal tumors, brain cancer, cervical cancer, colon cancer, rectal cancer, colorectal cancer, peritoneal cancer, biliary tract cancer, esophageal adenocarcinoma and esophageal cancer.

3. The use according to claim 2, wherein The solid tumor includes brain metastases of solid tumors.

4. The use according to any one of claims 1 to 3, wherein The drug can be used in combination with chemotherapy drugs or targeted drugs.

5. The use according to any one of claims 1 to 3, wherein The medicine is in the form of tablets, capsules, powders or injections.

6. Use of a composition for preparing a drug for preventing or treating HER2-positive solid tumors, wherein the composition comprises an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier 7. The use according to claim 6, wherein The solid tumors include breast cancer, gastric cancer, gastrointestinal cancer, esophageal gastric junction cancer, lung cancer, ovarian cancer, bladder cancer, tonsil tumors, oral cancer, laryngeal tumors, brain cancer, cervical cancer, colon cancer, rectal cancer, colorectal cancer, peritoneal cancer, biliary tract cancer, esophageal adenocarcinoma and esophageal cancer.

8. The use according to claim 7, wherein The solid tumor includes brain metastases of solid tumors.

9. The use according to any one of claims 6 to 8, wherein The drug can be used in combination with chemotherapy drugs or targeted drugs.

10. The use according to any one of claims 6 to 8, wherein The medicine is in the form of tablets, capsules, powders or injections.